A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2

A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2

Despite substantial advances in the treatment of acute myeloid leukemia (AML), only 30% of patients survive more than 5 years. Therefore, new therapeutics are much needed. Here, we present a novel therapeutic strategy targeting PR1, an HLA-A2 restricted myeloid leukemia antigen. Previously, we have...

Full description

Bibliographic Details
Main Authors: Amanda C. Herrmann, Jin S. Im, Sumedha Pareek, Wilfredo Ruiz-Vasquez, Sijie Lu, Anna Sergeeva, Jennifer Mehrens, Hong He, Gheath Alatrash, Pariya Sukhumalchandra, Lisa St. John, Karen Clise-Dwyer, Dongxing Zha, Jeffrey J. Molldrem
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Immunology
Subjects:
acute myeloid leukemia
bi-specific antibody
cancer immunotherapy
re-directed cytotoxicity
PR1
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.03153/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.03153/full

Similar Items